Cellyan Biotechnology Co., Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China. The company's services encompass the international sourcing and distribution of OTC medications, alongside comprehensive e-commerce supply chain management. Furthermore, it provides essential logistical support, including customs clearance, drug registration, and warehousing facilities. Cellyan Biotechnology caters to a diverse clientele, which includes logistics partners for e-commerce platforms, various merchants, and pharmaceutical distributors. Founded in 2023, the company is based in Yau Tong, Hong Kong. It was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and officially adopted the name Cellyan Biotechnology Co., Ltd in December 2025.
Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
Cellyan Biotechnology received a Nasdaq notification granting an additional 180-day grace period, expiring January 11, 2027, to regain compliance with the minimum $1.00 closing bid price requirement.
To cure the deficiency, the company must maintain a bid price of at least $1.00 for ten consecutive business days, though it noted a reverse share split may be necessary if natural price recovery fails.
Trading continues uninterrupted under ticker HKPD, but the company warned it cannot provide assurance that compliance will be restored.